SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with...
Vous n'êtes pas connecté
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with...
STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused...
Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of pulmonary hypertension (PH) and heart failure (HF), announced the...
– Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 – – EU...
PLYMOUTH MEETING, Pa., June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration...
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A...
People with type 2 diabetes who are treated with GLP-1 agonists have a decreased risk of developing dementia, according to a new study from...
A new study published in JAMA Network Open by an international cohort of researchers provides the latest data on the effectiveness of treating...
TUESDAY, June 25, 2024 -- A new slow-release pill form of ketamine can quell hard-to-treat depression without producing psychedelic side effects...
A new pill that releases ketamine slowly over time could treat severe depression without causing the psychedelic side effects often associated with...